Context Therapeutics (NASDAQ:CNTX) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Context Therapeutics (NASDAQ:CNTX) posted its earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01, reports.

Context Therapeutics Stock Up 0.2 %

Shares of CNTX stock traded up $0.00 during mid-day trading on Friday, reaching $0.77. The stock had a trading volume of 60,567 shares, compared to its average volume of 388,777. The firm’s 50 day simple moving average is $0.85 and its 200 day simple moving average is $1.44. Context Therapeutics has a one year low of $0.64 and a one year high of $2.75. The firm has a market cap of $57.88 million, a PE ratio of -0.85 and a beta of 2.06.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research report on Friday. JMP Securities started coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a report on Friday. Finally, Citizens Jmp upgraded shares of Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $6.17.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.